Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.

Literature DB >> 15793165

Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.

Gopal Muralidharan¹, Richard J Fruncillo, Marlynne Micalizzi, Donald G Raible, Steven M Troy.

Abstract

The pharmacokinetics of tigecycline was evaluated in 46 healthy young and elderly men and women. Except for the volumes of distribution at steady state (approximately 350 liters in women versus 500 liters in men), there were no significant differences in tigecycline pharmacokinetic parameters. Based on pharmacokinetics, no dosage adjustment is warranted based on age or sex.

Entities: Chemical Species

Mesh：

Substances：
Tigecycline
Minocycline

Year: 2005 PMID： 15793165 PMCID： PMC1068643 DOI： 10.1128/AAC.49.4.1656-1659.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

25 in total

Review 1. Age-dependent changes of the kidneys: pharmacological implications.

Authors: W Mühlberg; D Platt
Journal: Gerontology Date: 1999 Sep-Oct Impact factor: 5.140

2. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936.

Authors: R N Jones
Journal: Diagn Microbiol Infect Dis Date: 1999-11 Impact factor: 2.803

3. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors: Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal: Antimicrob Agents Chemother Date: 2005-01 Impact factor: 5.191

4. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines.

Authors: B A Rasmussen; Y Gluzman; F P Tally
Journal: Antimicrob Agents Chemother Date: 1994-07 Impact factor: 5.191

Review 5. Tetracyclines: antibiotic action, uptake, and resistance mechanisms.

Authors: D Schnappinger; W Hillen
Journal: Arch Microbiol Date: 1996-06 Impact factor: 2.552

6. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

Authors: R Patel; M S Rouse; K E Piper; J M Steckelberg
Journal: Diagn Microbiol Infect Dis Date: 2000-11 Impact factor: 2.803

7. Age and gender effects on the pharmacokinetics of gatifloxacin.

Authors: F P LaCreta; G D Kollia; G Duncan; D Behr; D M Grasela
Journal: Pharmacotherapy Date: 2000-06 Impact factor: 4.705

8. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors: M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal: Antimicrob Agents Chemother Date: 2000-04 Impact factor: 5.191

9. The influence of age on the pharmacokinetics of nimodipine.

Authors: W Mück; H P Breuel; J Kuhlmann
Journal: Int J Clin Pharmacol Ther Date: 1996-07 Impact factor: 1.366

Review 10. Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

Authors: B R Meyers; P Wilkinson
Journal: Clin Pharmacokinet Date: 1989-12 Impact factor: 6.447

16 in total

1. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Authors: S A Van Wart; J S Owen; E A Ludwig; A K Meagher; J M Korth-Bradley; B B Cirincione
Journal: Antimicrob Agents Chemother Date: 2006-08-28 Impact factor: 5.191

Review 2. Tigecycline.

Authors: James E Frampton; Monique P Curran
Journal: Drugs Date: 2005 Impact factor: 9.546

Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects.

Review 1. Age-dependent changes of the kidneys: pharmacological implications.

2. Disk diffusion susceptibility test development for the new glycylcycline, GAR-936.

3. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

4. Inhibition of protein synthesis occurring on tetracycline-resistant, TetM-protected ribosomes by a novel class of tetracyclines, the glycylcyclines.

Review 5. Tetracyclines: antibiotic action, uptake, and resistance mechanisms.

6. In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

7. Age and gender effects on the pharmacokinetics of gatifloxacin.

8. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

9. The influence of age on the pharmacokinetics of nimodipine.

Review 10. Clinical pharmacokinetics of antibacterial drugs in the elderly. Implications for selection and dosage.

1. Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.

Review 2. Tigecycline.

3. Tigecycline use in the outpatient parenteral antibiotic therapy setting.

4. In vitro activity of tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis.

5. Tigecycline (Tygacil): the first in the glycylcycline class of antibiotics.

6. Antimalarial activity of tigecycline, a novel glycylcycline antibiotic.

7. Tigecycline does not prolong corrected QT intervals in healthy subjects.

Review 8. Clinical pharmacokinetics and pharmacodynamics of tigecycline.

9. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin.

10. Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia.